<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant To Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 13, 1998
----------------
Xenometrix, Inc.
----------------
(Exact name of registrant as specified in its charter)
Delaware 1-14004 #04-3166089
-------- ------- -----------
(State or other (Commission (I.R.S. Employer
jurisdiction of incorporation) File Number) Identification No.)
2425 North 55th Street, Suite 111
Boulder, CO 80301
-----------------
(Address of principal executive offices,
including zip code)
(303) 447-1773
--------------
(Registrant's telephone number,
including area code)
<PAGE> 2
Item 5. Other Events
Xenometrix, Inc., (the "Company") announced that it has received notification of
a decision by the National Association of Securities Dealers to delist the
Company's securities from The Nasdaq Small-Cap Market, effective at the close of
business on January 12, 1998.
On January 13, 1998, the Company issued the attached press release, a copy of
which is included as Exhibit 99.1 to this Current Report and is incorporated by
reference herein.
Item 7. Exhibits
Exhibit
Number Description of Document
------- -----------------------
99.1 Press Release, dated January 13, 1998, announcing
Registrant's shares delisted from Nasdaq.
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
XENOMETRIX, INC.
By: /s/ Ronald L. Hendrick
Dated: January 23, 1998 Ronald L. Hendrick
Executive Vice President And
Chief Financial Officer
(Principal Financial and
Accounting Officer)
2
<PAGE> 3
EXHIBIT INDEX
Exhibit
Number Description of Document
------- -----------------------
99.1 Press Release, dated January 13, 1998, announcing
Registrant's shares delisted from Nasdaq.
<PAGE> 1
EXHIBIT 99.1
XENOMETRIX LOGO NEWS
- -------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE Xenometrix, Inc.
2425 North 55th Street
Boulder, CO 80301
Contract: Ron Hendrick, C.F.O. Telephone: (303) 447-1773
(303) 447-1773 EXT. 108 Facsimile: (303) 447-1758
XENOMETRIX SHARES DELISTED FROM NASDAQ
BOULDER, CO - JANUARY 13TH, 1998 - Xenometrix, Inc. (Boston Stock Exchange: XEN)
announced that it has received notification of the National Association of
Securities Dealers' decision to delist the Company's securities from The Nasdaq
Stock Market, effective at the close of business on January 12, 1998.
"The Company's total assets, capital and surplus had fallen below the minimum
required to maintain inclusion on the Nasdaq SmallCap Market," said President
and Chief Executive Officer Steve Sullivan. "Company representatives appeared
before a Nasdaq Listing Qualifications Panel on January 8 to request a brief
extension of time to enable the Company to eliminate the deficiencies. The
Company was notified late Monday afternoon of the panel's decision to deny the
request. The Company is currently evaluating whether or not to appeal the
panel's decision to the Nasdaq Listing and Hearing Review Committee," said
Sullivan.
"We were surprised and disappointed that Nasdaq has chosen this course of
action, as we had presented a plan to them which we believe would have enabled
the Company to achieve compliance. We will continue to pursue all reasonable
options for raising the capital needed to regain our listing and continue the
Company's operations. However, at this point, the Company cannot provide any
assurances in this regard. If additional capital is not forthcoming, we will
have to consider other options including, but not limited to, a significant
reduction or suspension of the Company's operations."
The Company's common shares and warrants will continue to be traded on the
Boston Stock Exchange under the symbols XEN and XENW, respectively. Effective
January 13, 1998, the Company's common shares and warrants will be quoted on the
OTC Bulletin Board under the symbol XENO and XENOW, respectively.
Xenometrix is a biotechnology company with proprietary gene expression profiling
technology used to help pharmaceutical and biotechnology companies to accelerate
the selection of the most promising drug leads.
###
